Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
Please always quote using this URN: urn:nbn:de:bvb:20-opus-354031
- Background Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensiveBackground Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab. Conclusion Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.…
Author: | Dominik Lehrieder, Nikolaos Zapantis, Mirko Pham, Michael Klaus Schuhmann, Axel Haarmann |
---|---|
URN: | urn:nbn:de:bvb:20-opus-354031 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Neurologische Klinik und Poliklinik |
Medizinische Fakultät / Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) | |
Language: | English |
Parent Title (English): | Frontiers in Neurology |
Year of Completion: | 2023 |
Volume: | 14 |
Article Number: | 1297341 |
Source: | Frontiers in Neurology (2023) 14:1297341. https://doi.org/10.3389/fneur.2023.1297341 |
DOI: | https://doi.org/10.3389/fneur.2023.1297341 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | AQP4; CD19; NMOSD; case report; inebilizumab; longitudinally extensive transverse myelitis; optic neuritis; seronegative |
Release Date: | 2024/05/31 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |